Catalyst Pharmaceutical Partners, Inc. announced the appointment of David D. Muth to the newly created position, Executive Vice President, Corporate Development. Mr. Muth will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst. As Executive Vice President, Corporate Development, Mr. Muth will be responsible for all of Catalyst’s corporate development activities and will work closely with the other members of the Catalyst team in preparing a commercialization strategy for Firdapse™.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=869114

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc.  announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw’s 16th Annual Global Investment Conference, which is being held on September 8-10, 2014 at The Palace Hotel in New York, NY.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=868808

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Brain GABA Levels, a potential surrogate marker of efficacy, will also be followed

Catalyst Pharmaceutical Partners, Inc. announced the initiation of its second Phase 1 safety and tolerance study for CPP-115, a novel GABA aminotransferase (GABA-AT) inhibitor.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=868500

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. reported financial results for the second quarter and six months ended June 30, 2014.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=866227

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Last Patient Completes 2-Week, Blinded Primary Treatment Period – Top-Line Data on Track to Report in 3Q14

100% of Patients Elected to Continue in 2-Year Open Label Follow-up Period

Catalyst Pharmaceutical Partners, Inc. provided an update on the progress of its Phase 3 study of FirdapseTM (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). The last patient has completed the blinded portion of the study and top-line data remains on track to be reported later this quarter. A total of 38 patients completed the 3 month treatment period and were successfully randomized to either receive FirdapseTM or placebo. All patients who were randomized elected to continue in 2-year open label follow-up.

Read release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=865474

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst today announced it will be presenting at the JMP Securities 2014 Healthcare Conference, in New York. Senior Management will provide an overview of the Company and its key programs on Tuesday, June 24th at 12:30 pm ET. The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation.

http://bit.ly/1qvkFLc

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst is set to join the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $5.2 trillion in assets are benchmarked to the Russell Indexes.

http://bit.ly/1pi60RN

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst’s Chief Executive Officer Patrick J. McEnany will provide a company overview and program update at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5 at 2:00 pm ET.

http://bit.ly/1gDnLJv

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

“This year to date has been a very productive period, as we have built on the momentum established last year,” said Patrick J. McEnany, Catalyst’s Chief Executive Officer.  “Some of the highlights include significantly augmenting our financial position through an offering of common stock resulting in our current cash and investments position of about $47 million.” 

Mr. McEnany added, “We continue to advance our Firdapse™ program to treat LEMS towards registration, and, assuming our Phase 3 trial is successful, we remain on track to begin our planned NDA submission in early 2015.  At the same time, we are progressing a number of pre-commercial activities in preparation for the planned future launch of Firdapse™.  We believe that Catalyst is well positioned to attain our goal of providing innovative medicines to market to improve the lives of patients with neuromuscular and neurological disorders.”

Catalyst continues to expect top-line data from the double-blind portion of our pivotal Phase 3 trial for Firdapse™ in the third quarter of this year.  Over the next several months, assuming the Phase 3 trial is successful, Catalyst will prepare an NDA submission which it expects to begin filing in early 2015.  As a benefit of its Breakthrough Therapy Designation, the FDA has asked the Company to file the NDA in modules on a rolling basis in order to expedite the review and approval process.

Catalyst continues to progress CPP-115 towards initiation of a Phase 1 multiple ascending dose safety and tolerance study, which the Company expects to commence during the third quarter.

http://bit.ly/1nRxi26

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Exhibits at AAN

We are exhibiting this week at the 66th American Academy of Neurology (AAN) Annual Meeting– the largest gathering of neurologists and neuroscience professionals– at the Pennsylvania Convention Center in Philadelphia. Exhibit hours are Tuesday, April 29 – Thursday, May 1.

Follow

Get every new post delivered to your Inbox.

Join 205 other followers

%d bloggers like this: